Module information
Botulinum Toxin Poisoning
Current author: Larry E. Davis, MD, FAAN, FACP
Module updated: 2009-12-29
CME expiration: 2012-12-29
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
References
Glossary
What's New
Patient Information
Guidelines and Systematic Reviews
What's New
ACP Members can access the full PIER website.

Newly Cited Reference2009-08-01
Electrophysiological diagnosis and patterns of response to treatment of botulism with neuromuscular respiratory failure.
Newly Cited Reference2009-06-15
Sensitivity of mouse bioassay in clinical wound botulism.
Newly Cited Reference2009-06-01
Botulinum neurotoxin: the ugly duckling.
Newly Cited Reference2009-04-01
Persistence of botulinum toxin in patients' serum: Alaska, 1959-2007.
Newly Cited Reference2008-06-20
The use of negative inspiratory force by ED personnel to monitor respiratory deterioration in the event of a botulism-induced MCI.
Newly Cited Reference2007-11-01
Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities.
Newly Cited Reference1984-05-01
Equine antitoxin use and other factors that predict outcome in type A foodborne botulism.
FAQs
The American College of Physicians is accredited by the Accreditation Council for continuing Medical Education (ACCME) to provide continuing education for physicians. The American College of Physicians designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity. Purpose: This activity has been developed for internists to facilitate the highest quality professional work in clinical applications, teaching, consultation, or research. Upon completion of the CME activity, participants should be able to demonstrate an increase in the skills and knowledge required to maintain competence, strengthen their habits of critical inquiry and balanced judgement, and to contribute to better patient care. Disclosures: Larry E. Davis, MD, FACN, FACP received honorarium from Merck & Co., provided expert testimony, received grants from the VA, NIH, and the University of New Mexico, received royalties from Fundamentals of Neurologic Disease. Deborah Korenstein, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Richard B. Lynn, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted © 2013 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.